Clinical trial IMpassion 030 (BIG 16-05/AFT-27/WO39391)
A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2016-003695-47 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03498716 |
| Inclusion criteria | Non-metastatic operable. TNBC. Adjuvant. Atezolizumab |
| Last update |